Scheduled Events
Oral Presentations
Session title:
Overall survival (OS) from ARCHES: Final analysis of the phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Oral Presentation No: LBA25
Session Date and Time:
Saturday,September 18 ,2021
2:20-2:30 PM CEST
Session title:
PALOMA-4: Primary results from a phase 3 trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)
Mini-Oral Presentation No: 228MO
Session Date and Time:
Saturday,September 18 ,2021
5:30-5:35 PM CEST
Session title:
Overall Survival (OS) of Palbociclib (P) plus Endocrine Therapy (ET) versus Capecitabine (CAP) in hormone receptor-positive/ HER2-negative metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs). Final results of the PEARL study
Mini-Oral Presentation No: 229MO
Session Date and Time:
Saturday,September 18 ,2021
5:55-6:00 PM CEST
Session title:
Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)
Mini-Oral Presentation No: 659MO
Session Date and Time:
Saturday, September 18, 2021
6:12 – 6:17 PM CEST
Session title:
Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): first analysis of randomized phase III GORTEC-REACH trial
Oral Presentation No: LBA35
Session Date and Time:
Monday, September 20, 2021
1:30 – 1:40 PM CEST
Session title:
SECOMBIT: the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma. A phase II randomized study.
Mini-Oral Presentation No: LBA40
Session Date and Time:
Monday, September 20, 2021
5:55 – 6:00 PM CEST
Session title:
5-year update on COLUMBUS: a randomized phase 3 trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
Mini-Oral Presentation No: 1041MO
Session Date and Time:
Monday, September 20, 2021
6:00 – 6:05 PM CEST
Session title:
Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib
Mini-Oral Presentation No: 122MO
Session Date and Time:
Monday, September 20, 2021
6:07 – 6:12 PM CEST
Session title:
COVID vaccine in cancer patients : Subgroup analysis of safety, immunogenicity and efficacy from a global Phase 3 randomized trial of the BNT162b2 trial
Oral Presentation No: 1558O
Session Date and Time:
Tuesday, September 21, 2021,1:30 – 1: 40 PM CEST
Session title:
The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs
Oral Presentation No: 1098O
Session Date and Time:
Tuesday, September 21, 2021
2:20 – 2:30 PM CEST
Symposia
Pfizer’s Sponsored Lung Symposia: Saturday, September 18, 2021 8:45-9:45 CEST
Pfizer’s Sponsored Breast Symposia: Saturday, September 18, 2021 10:30-12:00 CEST
Pfizer’s Sponsored Multiple Myeloma Symposia: Saturday, September 18, 2021 10:30-12:00 CEST
Pfizer’s Sponsored Bladder Symposia: Tuesday, September 21, 2021 10:30-11:45 CEST
Live Office Hours
Thursday, September 16, 2021
11:00 AM to 12:00 PM CEST
Monday, September 20, 2021
1:30 PM to 2:30 PM CEST
Tuesday, September 21, 2021
1:45 PM to 3:00 PM CEST
You have reached the Medical Information department at Pfizer. Personal data that you provide during this call will be processed within the Pfizer group and by our service providers in any country where we or they have facilities. Your personal data will be processed to handle your inquiry or complaint in accordance with our legitimate interests and, where otherwise applicable, to comply with our legal and regulatory obligations around reporting side effects, product complaints and patient safety. Please see our full Privacy Notice, available at EEA Medical Information, Product Complaints and Drug Safety | Pfizer Privacy Notice for more information about our privacy practices including how you can contact Pfizer’s data protection officer and request to exercise any rights you may have.If you wish to have a copy, you may request a copy to be sent via email or postal mail.
